Skip to main content

Jobs Job Match Companies People Locations Salaries Blog Resume Scanner Post a Job

Zero G Talent

Jobs
Job Match
Companies
People
Locations
Salaries
Blog
Resume Scanner
Post a Job

About
Contact
Privacy
Terms

© 2026 Zero G Talent. All rights reserved.

Home
People
Andrew Schiff

Andrew Schiff

Andrew Schiff

Managing Partner, Aisling Capital

New York, New York

About

Male

Andrew Schiff is the Managing Partner at Aisling Capital. He attended Columbia University, Cornell University, and Brown University.

Experience

Aisling Capital

Managing Partner · 1999 – present

31New York, New York, United StatesBiotechnology · Health Care

Monte Rosa Therapeutics

Advisor

IPO188Basel, Basel-Stadt, SwitzerlandBiotech/Pharma · Biotechnology

Board Member · Dren Bio
2022 – present
Board of Directors · Zeltiq Aesthetics
2010 – present
Board of Director · SkinMedica
2004 – present
Board of Directors · Adams Respiratory Therapeutics
Board of Directors · ArgiNOx Phamaceuticals
Director · ARMGO Pharma
Board of Directors · Asensus Surgical
Board of Directors · Barrier Therapeutics
Board of Directors · Bioenvision
Board of Directors · Cardiokine
Board of Directors · Cempra
Director · Colorescience
Director · Dynova Laboratories
Board of Directors · Miramar Labs
Board of Directors · Myogen
Director · Planet Technologies
Director · PowerVision
Board of Directors · Quintiles
Board of Directors · Sirion Therapeutics
Director · Zeltiq Aesthetics

Education

Columbia University · MBA, MBA
Cornell University · MD, Sass & Co.
Brown University · BS, Neuroscience

Aisling Capital Portfolio (1)

Monte Rosa Therapeutics

Biotech/PharmaIPO188 emp

People at Aisling Capital

Principal & Partner

Founder & Senior Advisor

Data from: crunchbase

Director of Investor Relations & Marketing

Scott Braunstein

Operating Partner

View all at Aisling Capital →

Latest from Andrew Schiff

Headlines from Google News. Social posts load from the platform only when you open a tab.

Gene therapy startup Forge Biologics raises $90M on biotech manufacturing strength
The Business Journals · Sep 13
Pfizer-Backed Dren Nets $65M to Advance Lead Asset to Clinic
BioSpace · Jun 14
Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic and to Accelerate Development of New Product Candidates from its Targeted Myeloid Engager and Phagocytosis Platform
Business Wire · Jun 14
With $1B already in for Dren Bio, Pfizer adds to pile in $65M financing
Fierce Biotech · Jun 14
Monte Rosa Therapeutics Closes $96 Million Series B Financing
Startupticker.ch · Sep 25